Enveda Biosciences, a Boulder, CO-based drug discovery and development company, raised an additional $51m in Series B1 equity financing.
Kinnevik led the Series B1 round, which also included participation by new investor Henry R. Kravis, the Co-Founder and Co-Executive Chairman of KKR. The round included participation from Enveda’s current major investors, including FPV, True Ventures, Dimension, and Wireframe.
The funding will enable Enveda to progress multiple platform-derived molecules to the clinic in 2023 and 2024 across inflammation, fibrosis, and neurosensory indications.
Led by Viswa Colluru, Ph.D., founder and CEO, and Mark Deeg, M.D., Ph.D., Chief Medical Officer, Enveda is a drug discovery and development company using the latest AI-powered technologies to uncover the ancient cache of medicines present in plants. The company’s proprietary platform solves the long-standing obstacles in natural product drug development including active molecule identification, property and structure prioritization, amenability to medicinal chemistry, and large-scale material access.
The closing of this Series B1 round brings the total capital that Enveda has raised to $175m.
FinSMEs
25/04/2023